. 2021 Sep 1;74(11):2001–2009. doi: 10.1093/cid/ciab744

Table 3.

Risk Factors for In Utero/Peripartum Human Immunodeficiency Virus (HIV) Transmission, a Multivariate Analysis

		In Utero/Peripartum Mothers		Unadjusted Conditional Logistic Regression		Adjusted Conditional Logistic Regression
Risk Factor	Total N = 191	Case N = 48	Control N = 143	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
Antepartum treatment regimen
Triple ART (PI-based)	83	11	72	Reference		Reference
Zidovudine + sdNVP +TDF/FTC tail	87	28	59	3.04 (1.41–6.55)	.005^a	4.54 (1.70–12.1)	.003^a
None (late presenter)	22	9	13	6.19 (1.82–21.1)	.004^a	9.82 (2.07–46.7)	.004^a
Genotype
Wild-type	162	44	118	Reference		Reference
Drug-Resistant	7	1	6	0.44 (.05–3.67)	.448	0.34 (.03–3.38)	.354
Missing genotype data	23	3	20	-		…
HIV RNA load at infant dagnosis
<4 log10 c/mL	98	24	74	Reference		Reference
≥4 log10 c/mL	74	23	51	1.36 (.70–2.65)	.367	1.00 (.38–2.63)	.988
Missing VL data	19	1	18	…		…
HIV RNA load at enrollment
<4 log10 c/mL	96	16	80	Reference		Reference
≥4 log10 c/mL	95	32	63	2.65 (1.31–5.35)	.007^a	3.45 (1.24–9.57)	.018^a
Enrollment CD4 count
≥500 cells/uL	105	24	81	Reference		Reference
<500 cells/uL	86	24	62	1.33 (.69–2.57)	.399	1.16 (.50–2.71)	.723

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; NVP, nevirapine; PI, protease inhibitor; TDF/FTC, tenofovir and emtricitabine.

^a P value < .05.